Fintel reports that on July 8, 2025, Scotiabank downgraded their outlook for Sage Therapeutics (NasdaqGM:SAGE) from Sector ...

Sage Therapeutics (SAGE) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

SUPN inks deal to acquire Sage Therapeutics for up to $795 million, securing rights to depression drug Zurzuvae.

Sage Therapeutics (SAGE) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Two weeks after Supernus unveiled the Sage Therapeutics acquisition, all 338 employees from the struggling biotech are being laid off.

Sage Therapeutics is a member of the Zacks Medical - Biomedical and Genetics industry. One other stock in the same industry, Compugen (CGEN), finished the last trading session 0.6% higher at $1.65.

Sage Therapeutics SAGE announced that Supernus Pharmaceuticals SUPN has agreed to acquire SAGE through a tender offer of $8.50 per share in cash, totaling around $561 million. Additionally ...

Sage Therapeutics cuts more than 330 jobs after announcing its $795 million acquisition The layoffs represent the majority of the Cambridge biotech’s workforce ...

After the FDA rejection of Zurzuvae in one type of depression and the triple failure of neuro asset dalzanemdor, Sage was ...

Sage Therapeutics shares gained 0.4% to trade at $9.11 on Tuesday. These analysts made changes to their price targets on Sage Therapeutics following acquisition announcement.

Sage Therapeutics Inc. said it plans to cut more than 300 jobs, less than two weeks after announcing it will be acquired.

The number of employees laid off and companies letting people go increased year over year during the first half of 2025.